Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.55 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280459 | 0.88 | MRGPRX1 (0.54) | MRGPRX1PTGS1PTGS2CYP19A1KDM4E | |
| SCHEMBL4575511 | 0.87 | PTGS1 (0.57) | SOS1MRGPRX1PTGS1PTGS2CYP19A1 | |
| SCHEMBL8107798 | 0.85 | PTGS2 (0.56) | SOS1PTGS1PTGS2CYP19A1CA1 | |
| SCHEMBL6599365 | 0.81 | PTGS2 (0.48) | MRGPRX1PTGS1PTGS2CYP19A1KDM4E | |
| SCHEMBL9657014 | 0.78 | MRGPRX1 (0.51) | MRGPRX1PTGS1PTGS2CYP19A1KDM4E | |
| SCHEMBL8105031 | 0.76 | SOS1 (0.59) | SOS1PTGS1PTGS2MAPTCA1 | |
| SCHEMBL8099526 | 0.75 | CYP19A1 (0.42) | MRGPRX1PTGS1PTGS2CYP19A1KDM4E | |
| SCHEMBL8101831 | 0.75 | MAPK1 (0.46) | PTGS1PTGS2CYP19A1KDM4EMEN1 | |
| SCHEMBL8107162 | 0.74 | PTGS1 (0.61) | PTGS1PTGS2CYP19A1LMNAADORA3 | |
| SCHEMBL11180303 | 0.74 | PTGS2 (0.52) | MRGPRX1PTGS1PTGS2CYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1520324-A | Antiangiogenic combination thereapy for treatment of cancer | — | 2004-08-11 | — | — | CN | claimed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | WASHINGTON UNIVERSITY | 2003-05-08 | — | — | US | claimed |
| WO-2003020268-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF CACHEXIA | WASHINGTON UNIVERSITY (US) | 2003-03-13 | — | — | WO | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| CN-1371286-A | Use of cyclooxygenase-2 inhibitor matrix metallappoteinase inhibitor antineoplastic agent and optionally radiation as combination treatment of neoplasia | SEARLE & CO (US) | 2002-09-25 | — | — | CN | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| CN-1346282-A | Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as combination therapy method in treating neoplasia | SEARLE & CO (US) | 2002-04-24 | — | — | CN | claimed |
| EP-1140192-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1140194-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINED TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| EP-1140179-A2 | USE OF A CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | claimed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1303308-B1 | ALDOSTERONE ANTAGONIST AND CYCLOOXYGENASE-2 INHIBITOR COMBINATION THERAPY TO PREVENT OR TREAT INFLAMMATION-RELATED CARDIOVASCULAR DISORDERS | PHARMACIA CORP (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | SOS1 3985/4885MRGPRX1 1954/4885PTGS1 6/4885 |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | TNF, PTGES2, PTGS2 | SOS1 4546/4885MRGPRX1 1435/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.